JP6818551B2 - Ｃｍｖワクチン - Google Patents
Ｃｍｖワクチン Download PDFInfo
- Publication number
- JP6818551B2 JP6818551B2 JP2016536893A JP2016536893A JP6818551B2 JP 6818551 B2 JP6818551 B2 JP 6818551B2 JP 2016536893 A JP2016536893 A JP 2016536893A JP 2016536893 A JP2016536893 A JP 2016536893A JP 6818551 B2 JP6818551 B2 JP 6818551B2
- Authority
- JP
- Japan
- Prior art keywords
- cmv
- glycoprotein
- arenavirus
- seq
- protein
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 229960005486 vaccine Drugs 0.000 title claims description 76
- 241000712891 Arenavirus Species 0.000 claims description 431
- 108091007433 antigens Proteins 0.000 claims description 417
- 102000036639 antigens Human genes 0.000 claims description 417
- 239000000427 antigen Substances 0.000 claims description 416
- 208000015181 infectious disease Diseases 0.000 claims description 316
- 239000012634 fragment Substances 0.000 claims description 306
- 108090000288 Glycoproteins Proteins 0.000 claims description 290
- 102000003886 Glycoproteins Human genes 0.000 claims description 285
- 230000010076 replication Effects 0.000 claims description 271
- 230000002950 deficient Effects 0.000 claims description 270
- 230000002458 infectious effect Effects 0.000 claims description 257
- 108090000623 proteins and genes Proteins 0.000 claims description 219
- 230000000890 antigenic effect Effects 0.000 claims description 218
- 102000004169 proteins and genes Human genes 0.000 claims description 197
- 239000013598 vector Substances 0.000 claims description 183
- 239000002773 nucleotide Substances 0.000 claims description 180
- 125000003729 nucleotide group Chemical group 0.000 claims description 172
- 108700026244 Open Reading Frames Proteins 0.000 claims description 147
- 150000007523 nucleic acids Chemical class 0.000 claims description 140
- 239000000203 mixture Substances 0.000 claims description 124
- 238000000034 method Methods 0.000 claims description 109
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 106
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 85
- 206010011831 Cytomegalovirus infection Diseases 0.000 claims description 67
- 241000700605 Viruses Species 0.000 claims description 65
- 239000013603 viral vector Substances 0.000 claims description 64
- 230000001086 cytosolic effect Effects 0.000 claims description 61
- 108020004707 nucleic acids Proteins 0.000 claims description 46
- 102000039446 nucleic acids Human genes 0.000 claims description 46
- 239000002245 particle Substances 0.000 claims description 43
- 241000701022 Cytomegalovirus Species 0.000 claims description 39
- 230000028993 immune response Effects 0.000 claims description 31
- 238000007918 intramuscular administration Methods 0.000 claims description 26
- 239000008194 pharmaceutical composition Substances 0.000 claims description 24
- 230000002163 immunogen Effects 0.000 claims description 22
- 238000011282 treatment Methods 0.000 claims description 20
- 238000012217 deletion Methods 0.000 claims description 18
- 230000037430 deletion Effects 0.000 claims description 18
- 206010010430 Congenital cytomegalovirus infection Diseases 0.000 claims description 14
- 230000035772 mutation Effects 0.000 claims description 12
- 238000004519 manufacturing process Methods 0.000 claims description 10
- 230000002265 prevention Effects 0.000 claims description 9
- 238000010255 intramuscular injection Methods 0.000 claims description 7
- 239000007927 intramuscular injection Substances 0.000 claims description 7
- 230000002068 genetic effect Effects 0.000 claims description 6
- 241000712899 Lymphocytic choriomeningitis mammarenavirus Species 0.000 claims description 5
- 230000015572 biosynthetic process Effects 0.000 claims description 5
- 230000005923 long-lasting effect Effects 0.000 claims description 4
- 101710186352 Probable membrane antigen 3 Proteins 0.000 claims 3
- 101710181078 Probable membrane antigen 75 Proteins 0.000 claims 3
- 101710178472 Tegument protein Proteins 0.000 claims 3
- 230000011218 segmentation Effects 0.000 claims 1
- 210000004027 cell Anatomy 0.000 description 160
- 108090000765 processed proteins & peptides Proteins 0.000 description 113
- 238000003776 cleavage reaction Methods 0.000 description 61
- 230000007017 scission Effects 0.000 description 61
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 57
- 230000007420 reactivation Effects 0.000 description 55
- 241000699670 Mus sp. Species 0.000 description 54
- 150000001413 amino acids Chemical class 0.000 description 48
- 238000003556 assay Methods 0.000 description 48
- 241001465754 Metazoa Species 0.000 description 44
- 239000002671 adjuvant Substances 0.000 description 43
- 210000002966 serum Anatomy 0.000 description 43
- DRTQHJPVMGBUCF-XVFCMESISA-N Uridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-XVFCMESISA-N 0.000 description 42
- 230000003053 immunization Effects 0.000 description 40
- 238000002649 immunization Methods 0.000 description 40
- 101100315698 Human cytomegalovirus (strain Merlin) UL131A gene Proteins 0.000 description 38
- 238000002965 ELISA Methods 0.000 description 35
- 230000014509 gene expression Effects 0.000 description 35
- 210000001744 T-lymphocyte Anatomy 0.000 description 34
- 230000000295 complement effect Effects 0.000 description 33
- 230000003472 neutralizing effect Effects 0.000 description 32
- 239000013612 plasmid Substances 0.000 description 32
- 238000002474 experimental method Methods 0.000 description 31
- 230000005867 T cell response Effects 0.000 description 30
- 102000004196 processed proteins & peptides Human genes 0.000 description 30
- 238000002255 vaccination Methods 0.000 description 29
- 230000003612 virological effect Effects 0.000 description 29
- 239000005090 green fluorescent protein Substances 0.000 description 26
- 102000004961 Furin Human genes 0.000 description 23
- 108090001126 Furin Proteins 0.000 description 23
- 241000701024 Human betaherpesvirus 5 Species 0.000 description 23
- 239000002299 complementary DNA Substances 0.000 description 23
- 108020004414 DNA Proteins 0.000 description 22
- DRTQHJPVMGBUCF-PSQAKQOGSA-N beta-L-uridine Natural products O[C@H]1[C@@H](O)[C@H](CO)O[C@@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-PSQAKQOGSA-N 0.000 description 21
- DRTQHJPVMGBUCF-UHFFFAOYSA-N uracil arabinoside Natural products OC1C(O)C(CO)OC1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-UHFFFAOYSA-N 0.000 description 21
- 229940045145 uridine Drugs 0.000 description 21
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 20
- 230000004044 response Effects 0.000 description 19
- 238000011144 upstream manufacturing Methods 0.000 description 19
- 241000699666 Mus <mouse, genus> Species 0.000 description 18
- 230000005847 immunogenicity Effects 0.000 description 17
- 238000013519 translation Methods 0.000 description 17
- 241000700198 Cavia Species 0.000 description 16
- 210000004899 c-terminal region Anatomy 0.000 description 16
- 238000002347 injection Methods 0.000 description 16
- 239000007924 injection Substances 0.000 description 16
- 230000005540 biological transmission Effects 0.000 description 15
- 239000000047 product Substances 0.000 description 15
- 125000006850 spacer group Chemical group 0.000 description 15
- 241000700199 Cavia porcellus Species 0.000 description 14
- 108020004684 Internal Ribosome Entry Sites Proteins 0.000 description 14
- 230000000694 effects Effects 0.000 description 14
- 238000000684 flow cytometry Methods 0.000 description 14
- 230000006698 induction Effects 0.000 description 14
- 238000006386 neutralization reaction Methods 0.000 description 14
- 102000007999 Nuclear Proteins Human genes 0.000 description 13
- 108010089610 Nuclear Proteins Proteins 0.000 description 13
- 108700005077 Viral Genes Proteins 0.000 description 13
- 230000027455 binding Effects 0.000 description 13
- 238000011597 hartley guinea pig Methods 0.000 description 13
- 108010029973 Lymphocytic choriomeningitis virus glycoprotein peptide Proteins 0.000 description 12
- 206010022000 influenza Diseases 0.000 description 12
- 238000002360 preparation method Methods 0.000 description 12
- 238000010790 dilution Methods 0.000 description 11
- 239000012895 dilution Substances 0.000 description 11
- 230000001605 fetal effect Effects 0.000 description 11
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 10
- 210000003771 C cell Anatomy 0.000 description 10
- 102000004127 Cytokines Human genes 0.000 description 10
- 108090000695 Cytokines Proteins 0.000 description 10
- -1 IFN-g Proteins 0.000 description 10
- 241000283973 Oryctolagus cuniculus Species 0.000 description 10
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 10
- 108020001507 fusion proteins Proteins 0.000 description 10
- 102000037865 fusion proteins Human genes 0.000 description 10
- 239000000523 sample Substances 0.000 description 10
- 210000004988 splenocyte Anatomy 0.000 description 10
- 208000024891 symptom Diseases 0.000 description 10
- 229940104230 thymidine Drugs 0.000 description 10
- 101710154606 Hemagglutinin Proteins 0.000 description 9
- 101710093908 Outer capsid protein VP4 Proteins 0.000 description 9
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 description 9
- 101710176177 Protein A56 Proteins 0.000 description 9
- 108700019146 Transgenes Proteins 0.000 description 9
- 230000005875 antibody response Effects 0.000 description 9
- 238000001514 detection method Methods 0.000 description 9
- 201000010099 disease Diseases 0.000 description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 9
- 239000002609 medium Substances 0.000 description 9
- 238000012360 testing method Methods 0.000 description 9
- 241000283707 Capra Species 0.000 description 8
- 241000283074 Equus asinus Species 0.000 description 8
- 241000272186 Falco columbarius Species 0.000 description 8
- 125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 description 8
- 230000024932 T cell mediated immunity Effects 0.000 description 8
- 210000000987 immune system Anatomy 0.000 description 8
- 230000036039 immunity Effects 0.000 description 8
- 230000035935 pregnancy Effects 0.000 description 8
- 241000712461 unidentified influenza virus Species 0.000 description 8
- 101710141347 Major envelope glycoprotein Proteins 0.000 description 7
- 241000585245 Methylophaga aminisulfidivorans Species 0.000 description 7
- 108091023040 Transcription factor Proteins 0.000 description 7
- 102100040247 Tumor necrosis factor Human genes 0.000 description 7
- 238000011161 development Methods 0.000 description 7
- 239000013613 expression plasmid Substances 0.000 description 7
- 238000011534 incubation Methods 0.000 description 7
- 239000012528 membrane Substances 0.000 description 7
- 238000013518 transcription Methods 0.000 description 7
- 230000035897 transcription Effects 0.000 description 7
- 238000001262 western blot Methods 0.000 description 7
- 206010010356 Congenital anomaly Diseases 0.000 description 6
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- 238000011529 RT qPCR Methods 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 6
- 238000010171 animal model Methods 0.000 description 6
- 239000000872 buffer Substances 0.000 description 6
- 239000006185 dispersion Substances 0.000 description 6
- 230000001939 inductive effect Effects 0.000 description 6
- 230000004048 modification Effects 0.000 description 6
- 238000012986 modification Methods 0.000 description 6
- 238000010186 staining Methods 0.000 description 6
- 108091008048 CMVpp65 Proteins 0.000 description 5
- 238000011510 Elispot assay Methods 0.000 description 5
- 108060003393 Granulin Proteins 0.000 description 5
- 102000000588 Interleukin-2 Human genes 0.000 description 5
- 108010002350 Interleukin-2 Proteins 0.000 description 5
- 102000017143 RNA Polymerase I Human genes 0.000 description 5
- 108010013845 RNA Polymerase I Proteins 0.000 description 5
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 5
- 230000000692 anti-sense effect Effects 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 230000007812 deficiency Effects 0.000 description 5
- 238000003114 enzyme-linked immunosorbent spot assay Methods 0.000 description 5
- 239000013604 expression vector Substances 0.000 description 5
- 239000000499 gel Substances 0.000 description 5
- 238000011554 guinea pig model Methods 0.000 description 5
- 230000002779 inactivation Effects 0.000 description 5
- 229920001184 polypeptide Polymers 0.000 description 5
- 230000001681 protective effect Effects 0.000 description 5
- 230000001105 regulatory effect Effects 0.000 description 5
- 210000004989 spleen cell Anatomy 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- 229940125575 vaccine candidate Drugs 0.000 description 5
- 230000029812 viral genome replication Effects 0.000 description 5
- 125000001433 C-terminal amino-acid group Chemical group 0.000 description 4
- 101001065501 Escherichia phage MS2 Lysis protein Proteins 0.000 description 4
- 108091006027 G proteins Proteins 0.000 description 4
- 102000030782 GTP binding Human genes 0.000 description 4
- 108091000058 GTP-Binding Proteins 0.000 description 4
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 4
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 4
- 241000282412 Homo Species 0.000 description 4
- 102100037850 Interferon gamma Human genes 0.000 description 4
- 108010074328 Interferon-gamma Proteins 0.000 description 4
- 206010023126 Jaundice Diseases 0.000 description 4
- 102000011931 Nucleoproteins Human genes 0.000 description 4
- 108010061100 Nucleoproteins Proteins 0.000 description 4
- 241000709664 Picornaviridae Species 0.000 description 4
- 102000009572 RNA Polymerase II Human genes 0.000 description 4
- 210000003719 b-lymphocyte Anatomy 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 238000013461 design Methods 0.000 description 4
- 210000001508 eye Anatomy 0.000 description 4
- 230000001024 immunotherapeutic effect Effects 0.000 description 4
- 230000001965 increasing effect Effects 0.000 description 4
- 210000004072 lung Anatomy 0.000 description 4
- 230000000527 lymphocytic effect Effects 0.000 description 4
- 210000004962 mammalian cell Anatomy 0.000 description 4
- 239000003550 marker Substances 0.000 description 4
- ZJAOAACCNHFJAH-UHFFFAOYSA-N phosphonoformic acid Chemical compound OC(=O)P(O)(O)=O ZJAOAACCNHFJAH-UHFFFAOYSA-N 0.000 description 4
- 230000005180 public health Effects 0.000 description 4
- RXWNCPJZOCPEPQ-NVWDDTSBSA-N puromycin Chemical compound C1=CC(OC)=CC=C1C[C@H](N)C(=O)N[C@H]1[C@@H](O)[C@H](N2C3=NC=NC(=C3N=C2)N(C)C)O[C@@H]1CO RXWNCPJZOCPEPQ-NVWDDTSBSA-N 0.000 description 4
- 238000003753 real-time PCR Methods 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 210000003705 ribosome Anatomy 0.000 description 4
- 238000010561 standard procedure Methods 0.000 description 4
- 230000000638 stimulation Effects 0.000 description 4
- 238000007920 subcutaneous administration Methods 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- 210000000689 upper leg Anatomy 0.000 description 4
- 108020005345 3' Untranslated Regions Proteins 0.000 description 3
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 3
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 3
- 241000710929 Alphavirus Species 0.000 description 3
- 208000031504 Asymptomatic Infections Diseases 0.000 description 3
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 3
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 3
- 241000702421 Dependoparvovirus Species 0.000 description 3
- 241000991587 Enterovirus C Species 0.000 description 3
- 241000710198 Foot-and-mouth disease virus Species 0.000 description 3
- 206010020751 Hypersensitivity Diseases 0.000 description 3
- 206010062016 Immunosuppression Diseases 0.000 description 3
- 108060004795 Methyltransferase Proteins 0.000 description 3
- 241000711408 Murine respirovirus Species 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- 108020000999 Viral RNA Proteins 0.000 description 3
- 230000007815 allergy Effects 0.000 description 3
- 230000003092 anti-cytokine Effects 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 239000006285 cell suspension Substances 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 238000012258 culturing Methods 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 208000006454 hepatitis Diseases 0.000 description 3
- 231100000283 hepatitis Toxicity 0.000 description 3
- 230000001506 immunosuppresive effect Effects 0.000 description 3
- 230000003834 intracellular effect Effects 0.000 description 3
- 210000004698 lymphocyte Anatomy 0.000 description 3
- 210000002540 macrophage Anatomy 0.000 description 3
- 230000013011 mating Effects 0.000 description 3
- 229940035032 monophosphoryl lipid a Drugs 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 238000002962 plaque-reduction assay Methods 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- 230000002062 proliferating effect Effects 0.000 description 3
- 230000000644 propagated effect Effects 0.000 description 3
- 210000003079 salivary gland Anatomy 0.000 description 3
- 229930182490 saponin Natural products 0.000 description 3
- 150000007949 saponins Chemical class 0.000 description 3
- 235000017709 saponins Nutrition 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 238000007619 statistical method Methods 0.000 description 3
- 238000010254 subcutaneous injection Methods 0.000 description 3
- 239000007929 subcutaneous injection Substances 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 241000701161 unidentified adenovirus Species 0.000 description 3
- 241001529453 unidentified herpesvirus Species 0.000 description 3
- 230000009385 viral infection Effects 0.000 description 3
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 2
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 2
- 108020003589 5' Untranslated Regions Proteins 0.000 description 2
- 102000007469 Actins Human genes 0.000 description 2
- 108010085238 Actins Proteins 0.000 description 2
- 241000282472 Canis lupus familiaris Species 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 206010008761 Choriomeningitis lymphocytic Diseases 0.000 description 2
- 108091026890 Coding region Proteins 0.000 description 2
- 206010062343 Congenital infection Diseases 0.000 description 2
- 206010011878 Deafness Diseases 0.000 description 2
- 102100038132 Endogenous retrovirus group K member 6 Pro protein Human genes 0.000 description 2
- 241000282326 Felis catus Species 0.000 description 2
- 206010061459 Gastrointestinal ulcer Diseases 0.000 description 2
- 108010054147 Hemoglobins Proteins 0.000 description 2
- 102000001554 Hemoglobins Human genes 0.000 description 2
- 101900312118 Human cytomegalovirus Envelope glycoprotein H Proteins 0.000 description 2
- 208000032420 Latent Infection Diseases 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 239000000020 Nitrocellulose Substances 0.000 description 2
- 108091005804 Peptidases Proteins 0.000 description 2
- 206010035664 Pneumonia Diseases 0.000 description 2
- 101150076840 PolI gene Proteins 0.000 description 2
- 239000004365 Protease Substances 0.000 description 2
- 108010009460 RNA Polymerase II Proteins 0.000 description 2
- 102000014450 RNA Polymerase III Human genes 0.000 description 2
- 108010078067 RNA Polymerase III Proteins 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 241001068295 Replication defective viruses Species 0.000 description 2
- 108700008625 Reporter Genes Proteins 0.000 description 2
- 230000006052 T cell proliferation Effects 0.000 description 2
- 241000723792 Tobacco etch virus Species 0.000 description 2
- 101710120037 Toxin CcdB Proteins 0.000 description 2
- WPVFJKSGQUFQAP-GKAPJAKFSA-N Valcyte Chemical compound N1C(N)=NC(=O)C2=C1N(COC(CO)COC(=O)[C@@H](N)C(C)C)C=N2 WPVFJKSGQUFQAP-GKAPJAKFSA-N 0.000 description 2
- 206010058874 Viraemia Diseases 0.000 description 2
- 208000036142 Viral infection Diseases 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 239000000443 aerosol Substances 0.000 description 2
- 208000026935 allergic disease Diseases 0.000 description 2
- 210000000612 antigen-presenting cell Anatomy 0.000 description 2
- 208000006673 asthma Diseases 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 210000005013 brain tissue Anatomy 0.000 description 2
- 239000001506 calcium phosphate Substances 0.000 description 2
- 229910000389 calcium phosphate Inorganic materials 0.000 description 2
- 235000011010 calcium phosphates Nutrition 0.000 description 2
- 108091092328 cellular RNA Proteins 0.000 description 2
- 239000012228 culture supernatant Substances 0.000 description 2
- 238000005520 cutting process Methods 0.000 description 2
- 238000004163 cytometry Methods 0.000 description 2
- 208000037771 disease arising from reactivation of latent virus Diseases 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- 210000002889 endothelial cell Anatomy 0.000 description 2
- 210000002919 epithelial cell Anatomy 0.000 description 2
- 210000002950 fibroblast Anatomy 0.000 description 2
- 238000000799 fluorescence microscopy Methods 0.000 description 2
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 2
- 229960005102 foscarnet Drugs 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- 229960002963 ganciclovir Drugs 0.000 description 2
- IRSCQMHQWWYFCW-UHFFFAOYSA-N ganciclovir Chemical compound O=C1NC(N)=NC2=C1N=CN2COC(CO)CO IRSCQMHQWWYFCW-UHFFFAOYSA-N 0.000 description 2
- 231100000888 hearing loss Toxicity 0.000 description 2
- 230000010370 hearing loss Effects 0.000 description 2
- 208000016354 hearing loss disease Diseases 0.000 description 2
- 230000001771 impaired effect Effects 0.000 description 2
- 238000011081 inoculation Methods 0.000 description 2
- 229910017053 inorganic salt Inorganic materials 0.000 description 2
- 238000010212 intracellular staining Methods 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 208000001419 lymphocytic choriomeningitis Diseases 0.000 description 2
- 108010026228 mRNA guanylyltransferase Proteins 0.000 description 2
- 230000008774 maternal effect Effects 0.000 description 2
- 229920000609 methyl cellulose Polymers 0.000 description 2
- 239000001923 methylcellulose Substances 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 238000011587 new zealand white rabbit Methods 0.000 description 2
- 229920001220 nitrocellulos Polymers 0.000 description 2
- 238000002559 palpation Methods 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 210000002826 placenta Anatomy 0.000 description 2
- 230000003169 placental effect Effects 0.000 description 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
- 230000008488 polyadenylation Effects 0.000 description 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 2
- 229920000053 polysorbate 80 Polymers 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 239000003380 propellant Substances 0.000 description 2
- 229950010131 puromycin Drugs 0.000 description 2
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 210000003289 regulatory T cell Anatomy 0.000 description 2
- 230000003362 replicative effect Effects 0.000 description 2
- 229920002477 rna polymer Polymers 0.000 description 2
- 238000013207 serial dilution Methods 0.000 description 2
- LPXPTNMVRIOKMN-UHFFFAOYSA-M sodium nitrite Substances [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 230000000153 supplemental effect Effects 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 2
- 229940033663 thimerosal Drugs 0.000 description 2
- 238000003146 transient transfection Methods 0.000 description 2
- 230000001296 transplacental effect Effects 0.000 description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- 229960002149 valganciclovir Drugs 0.000 description 2
- YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 description 1
- DDMOUSALMHHKOS-UHFFFAOYSA-N 1,2-dichloro-1,1,2,2-tetrafluoroethane Chemical compound FC(F)(Cl)C(F)(F)Cl DDMOUSALMHHKOS-UHFFFAOYSA-N 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- QRXMUCSWCMTJGU-UHFFFAOYSA-N 5-bromo-4-chloro-3-indolyl phosphate Chemical compound C1=C(Br)C(Cl)=C2C(OP(O)(=O)O)=CNC2=C1 QRXMUCSWCMTJGU-UHFFFAOYSA-N 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 241000190711 Amapari mammarenavirus Species 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 208000005989 Arenaviridae Infections Diseases 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 241001440626 Bear Canyon mammarenavirus Species 0.000 description 1
- 201000004569 Blindness Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 241000710190 Cardiovirus Species 0.000 description 1
- 241001467055 Caviid betaherpesvirus 2 Species 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 208000002691 Choroiditis Diseases 0.000 description 1
- 206010010071 Coma Diseases 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 108091035707 Consensus sequence Proteins 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 241000724252 Cucumber mosaic virus Species 0.000 description 1
- 206010058854 Cytomegalovirus viraemia Diseases 0.000 description 1
- 206010011891 Deafness neurosensory Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 239000004338 Dichlorodifluoromethane Substances 0.000 description 1
- 201000010374 Down Syndrome Diseases 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 241000701867 Enterobacteria phage T7 Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000214054 Equine rhinitis A virus Species 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 208000001362 Fetal Growth Retardation Diseases 0.000 description 1
- 241000190598 Flexal mammarenavirus Species 0.000 description 1
- 206010016845 Foetal alcohol syndrome Diseases 0.000 description 1
- 206010070531 Foetal growth restriction Diseases 0.000 description 1
- 101150117028 GP gene Proteins 0.000 description 1
- 208000012671 Gastrointestinal haemorrhages Diseases 0.000 description 1
- 208000031886 HIV Infections Diseases 0.000 description 1
- 208000037357 HIV infectious disease Diseases 0.000 description 1
- 239000012981 Hank's balanced salt solution Substances 0.000 description 1
- 101000802734 Homo sapiens eIF5-mimic protein 2 Proteins 0.000 description 1
- 102000004157 Hydrolases Human genes 0.000 description 1
- 108090000604 Hydrolases Proteins 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- 206010021882 Infections and infestations congenital Diseases 0.000 description 1
- 241000712431 Influenza A virus Species 0.000 description 1
- 241000713196 Influenza B virus Species 0.000 description 1
- 241000713297 Influenza C virus Species 0.000 description 1
- 241000555269 Ippy mammarenavirus Species 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 241000712902 Lassa mammarenavirus Species 0.000 description 1
- 241000190596 Latino mammarenavirus Species 0.000 description 1
- 108091026898 Leader sequence (mRNA) Proteins 0.000 description 1
- 241000712898 Machupo mammarenavirus Species 0.000 description 1
- 238000000585 Mann–Whitney U test Methods 0.000 description 1
- 208000036626 Mental retardation Diseases 0.000 description 1
- 241000712897 Mopeia mammarenavirus Species 0.000 description 1
- 208000000112 Myalgia Diseases 0.000 description 1
- 208000009525 Myocarditis Diseases 0.000 description 1
- 208000029726 Neurodevelopmental disease Diseases 0.000 description 1
- 108020004485 Nonsense Codon Proteins 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 241000146363 Oliveros mammarenavirus Species 0.000 description 1
- 208000007117 Oral Ulcer Diseases 0.000 description 1
- 206010068319 Oropharyngeal pain Diseases 0.000 description 1
- 241000190594 Parana mammarenavirus Species 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 208000037581 Persistent Infection Diseases 0.000 description 1
- 201000007100 Pharyngitis Diseases 0.000 description 1
- 108010076039 Polyproteins Proteins 0.000 description 1
- 208000003971 Posterior uveitis Diseases 0.000 description 1
- 241001533393 Potyviridae Species 0.000 description 1
- 208000005107 Premature Birth Diseases 0.000 description 1
- 101710201688 Protein UL131A Proteins 0.000 description 1
- 206010037549 Purpura Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 239000012083 RIPA buffer Substances 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 206010038910 Retinitis Diseases 0.000 description 1
- 239000012891 Ringer solution Substances 0.000 description 1
- 235000011449 Rosa Nutrition 0.000 description 1
- 208000009966 Sensorineural Hearing Loss Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- 206010042674 Swelling Diseases 0.000 description 1
- 241000190592 Tamiami mammarenavirus Species 0.000 description 1
- BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 description 1
- 108091036066 Three prime untranslated region Proteins 0.000 description 1
- 206010052779 Transplant rejections Diseases 0.000 description 1
- 206010044688 Trisomy 21 Diseases 0.000 description 1
- 108091023045 Untranslated Region Proteins 0.000 description 1
- 108010067390 Viral Proteins Proteins 0.000 description 1
- 241000205658 Whitewater Arroyo mammarenavirus Species 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000003044 adaptive effect Effects 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical class [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- ILRRQNADMUWWFW-UHFFFAOYSA-K aluminium phosphate Chemical compound O1[Al]2OP1(=O)O2 ILRRQNADMUWWFW-UHFFFAOYSA-K 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 208000002399 aphthous stomatitis Diseases 0.000 description 1
- 230000004596 appetite loss Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 description 1
- 108010030694 avidin-horseradish peroxidase complex Proteins 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 229940031416 bivalent vaccine Drugs 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 230000002308 calcification Effects 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 229960004424 carbon dioxide Drugs 0.000 description 1
- 229910002091 carbon monoxide Inorganic materials 0.000 description 1
- 230000020411 cell activation Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 230000006037 cell lysis Effects 0.000 description 1
- 239000013553 cell monolayer Substances 0.000 description 1
- 238000001516 cell proliferation assay Methods 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 201000004709 chorioretinitis Diseases 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 230000001010 compromised effect Effects 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 230000016396 cytokine production Effects 0.000 description 1
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- BUACSMWVFUNQET-UHFFFAOYSA-H dialuminum;trisulfate;hydrate Chemical compound O.[Al+3].[Al+3].[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O BUACSMWVFUNQET-UHFFFAOYSA-H 0.000 description 1
- 229910003460 diamond Inorganic materials 0.000 description 1
- 239000010432 diamond Substances 0.000 description 1
- PXBRQCKWGAHEHS-UHFFFAOYSA-N dichlorodifluoromethane Chemical compound FC(F)(Cl)Cl PXBRQCKWGAHEHS-UHFFFAOYSA-N 0.000 description 1
- 235000019404 dichlorodifluoromethane Nutrition 0.000 description 1
- 229940042935 dichlorodifluoromethane Drugs 0.000 description 1
- 229940087091 dichlorotetrafluoroethane Drugs 0.000 description 1
- 210000002249 digestive system Anatomy 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N dodecahydrosqualene Natural products CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 241001493065 dsRNA viruses Species 0.000 description 1
- 102100035859 eIF5-mimic protein 2 Human genes 0.000 description 1
- 210000005069 ears Anatomy 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 206010014599 encephalitis Diseases 0.000 description 1
- 210000003238 esophagus Anatomy 0.000 description 1
- 208000026934 fetal alcohol spectrum disease Diseases 0.000 description 1
- 201000007794 fetal alcohol syndrome Diseases 0.000 description 1
- 208000030941 fetal growth restriction Diseases 0.000 description 1
- MUJOIMFVNIBMKC-UHFFFAOYSA-N fludioxonil Chemical compound C=12OC(F)(F)OC2=CC=CC=1C1=CNC=C1C#N MUJOIMFVNIBMKC-UHFFFAOYSA-N 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 101150055782 gH gene Proteins 0.000 description 1
- 208000030304 gastrointestinal bleeding Diseases 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 238000012239 gene modification Methods 0.000 description 1
- 230000005017 genetic modification Effects 0.000 description 1
- 235000013617 genetically modified food Nutrition 0.000 description 1
- 230000000762 glandular Effects 0.000 description 1
- 238000001631 haemodialysis Methods 0.000 description 1
- 239000000185 hemagglutinin Substances 0.000 description 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
- 230000000322 hemodialysis Effects 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 230000006801 homologous recombination Effects 0.000 description 1
- 238000002744 homologous recombination Methods 0.000 description 1
- 230000007236 host immunity Effects 0.000 description 1
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 1
- 235000020256 human milk Nutrition 0.000 description 1
- 210000004251 human milk Anatomy 0.000 description 1
- 230000028996 humoral immune response Effects 0.000 description 1
- 230000008348 humoral response Effects 0.000 description 1
- 230000036543 hypotension Effects 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 230000008088 immune pathway Effects 0.000 description 1
- 230000006058 immune tolerance Effects 0.000 description 1
- 230000007365 immunoregulation Effects 0.000 description 1
- 230000003308 immunostimulating effect Effects 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 229940124589 immunosuppressive drug Drugs 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 210000003000 inclusion body Anatomy 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 238000007917 intracranial administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 230000021633 leukocyte mediated immunity Effects 0.000 description 1
- 229940124590 live attenuated vaccine Drugs 0.000 description 1
- 229940023012 live-attenuated vaccine Drugs 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 235000021266 loss of appetite Nutrition 0.000 description 1
- 208000019017 loss of appetite Diseases 0.000 description 1
- 210000004324 lymphatic system Anatomy 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- KJFBVJALEQWJBS-XUXIUFHCSA-N maribavir Chemical compound CC(C)NC1=NC2=CC(Cl)=C(Cl)C=C2N1[C@H]1O[C@@H](CO)[C@H](O)[C@@H]1O KJFBVJALEQWJBS-XUXIUFHCSA-N 0.000 description 1
- 229960003762 maribavir Drugs 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 150000002730 mercury Chemical class 0.000 description 1
- 208000004141 microcephaly Diseases 0.000 description 1
- 238000001000 micrograph Methods 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000009126 molecular therapy Methods 0.000 description 1
- 229940126619 mouse monoclonal antibody Drugs 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 239000006199 nebulizer Substances 0.000 description 1
- 230000020342 negative regulation of protein transport Effects 0.000 description 1
- 230000037434 nonsense mutation Effects 0.000 description 1
- 230000009871 nonspecific binding Effects 0.000 description 1
- 238000010899 nucleation Methods 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000007918 pathogenicity Effects 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 230000009984 peri-natal effect Effects 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 206010034754 petechiae Diseases 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000007505 plaque formation Effects 0.000 description 1
- 239000013600 plasmid vector Substances 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 229940068968 polysorbate 80 Drugs 0.000 description 1
- 230000002516 postimmunization Effects 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 238000009021 pre-vaccination Methods 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 238000007859 qualitative PCR Methods 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000007115 recruitment Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000012723 sample buffer Substances 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 231100000879 sensorineural hearing loss Toxicity 0.000 description 1
- 208000023573 sensorineural hearing loss disease Diseases 0.000 description 1
- 208000013220 shortness of breath Diseases 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 230000003393 splenic effect Effects 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- 229940031439 squalene Drugs 0.000 description 1
- TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 description 1
- 230000010473 stable expression Effects 0.000 description 1
- 238000003153 stable transfection Methods 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 229940031626 subunit vaccine Drugs 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 238000004114 suspension culture Methods 0.000 description 1
- 210000004243 sweat Anatomy 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 239000011885 synergistic combination Substances 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- 210000001138 tear Anatomy 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 206010043554 thrombocytopenia Diseases 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 210000003412 trans-golgi network Anatomy 0.000 description 1
- 238000003151 transfection method Methods 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000010474 transient expression Effects 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- CYRMSUTZVYGINF-UHFFFAOYSA-N trichlorofluoromethane Chemical compound FC(Cl)(Cl)Cl CYRMSUTZVYGINF-UHFFFAOYSA-N 0.000 description 1
- 229940029284 trichlorofluoromethane Drugs 0.000 description 1
- 238000011870 unpaired t-test Methods 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 230000007502 viral entry Effects 0.000 description 1
- 239000004034 viscosity adjusting agent Substances 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
- 208000016261 weight loss Diseases 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 101150069452 z gene Proteins 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/245—Herpetoviridae, e.g. herpes simplex virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5254—Virus avirulent or attenuated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
- C12N2710/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/10011—Arenaviridae
- C12N2760/10021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/10011—Arenaviridae
- C12N2760/10041—Use of virus, viral particle or viral elements as a vector
- C12N2760/10043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2840/00—Vectors comprising a special translation-regulating system
- C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2840/00—Vectors comprising a special translation-regulating system
- C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
- C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES
- C12N2840/206—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES having multiple IRES
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Biomedical Technology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361911135P | 2013-12-03 | 2013-12-03 | |
| US61/911,135 | 2013-12-03 | ||
| US201462055699P | 2014-09-26 | 2014-09-26 | |
| US62/055,699 | 2014-09-26 | ||
| PCT/EP2014/076466 WO2015082570A1 (en) | 2013-12-03 | 2014-12-03 | Cmv vaccines |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020218641A Division JP7001807B2 (ja) | 2013-12-03 | 2020-12-28 | Ｃｍｖワクチン |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017503482A JP2017503482A (ja) | 2017-02-02 |
| JP2017503482A5 JP2017503482A5 (OSRAM) | 2018-01-18 |
| JP6818551B2 true JP6818551B2 (ja) | 2021-01-20 |
Family
ID=52232138
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016536893A Active JP6818551B2 (ja) | 2013-12-03 | 2014-12-03 | Ｃｍｖワクチン |
| JP2020218641A Active JP7001807B2 (ja) | 2013-12-03 | 2020-12-28 | Ｃｍｖワクチン |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020218641A Active JP7001807B2 (ja) | 2013-12-03 | 2020-12-28 | Ｃｍｖワクチン |
Country Status (17)
| Country | Link |
|---|---|
| US (3) | US10111945B2 (OSRAM) |
| EP (2) | EP3077519B1 (OSRAM) |
| JP (2) | JP6818551B2 (OSRAM) |
| CN (2) | CN115058452A (OSRAM) |
| AU (2) | AU2014359276B2 (OSRAM) |
| CA (1) | CA2932318C (OSRAM) |
| CY (1) | CY1124288T1 (OSRAM) |
| DK (1) | DK3077519T3 (OSRAM) |
| ES (1) | ES2868427T3 (OSRAM) |
| HR (1) | HRP20211015T1 (OSRAM) |
| HU (1) | HUE054579T2 (OSRAM) |
| LT (1) | LT3077519T (OSRAM) |
| PL (1) | PL3077519T3 (OSRAM) |
| PT (1) | PT3077519T (OSRAM) |
| RS (1) | RS61993B1 (OSRAM) |
| SI (1) | SI3077519T1 (OSRAM) |
| WO (1) | WO2015082570A1 (OSRAM) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2438773T3 (es) | 2007-12-27 | 2014-01-20 | Universität Zürich | Vectores arenavíricos defectuosos en la replicación |
| US10023626B2 (en) | 2013-09-30 | 2018-07-17 | Modernatx, Inc. | Polynucleotides encoding immune modulating polypeptides |
| PL3077519T3 (pl) * | 2013-12-03 | 2021-10-18 | Hookipa Biotech Gmbh | Szczepionki CMV |
| US10722564B2 (en) | 2014-11-13 | 2020-07-28 | Université de Genéve | Tri-segmented arenaviruses as vaccine vectors |
| EP3031822A1 (en) * | 2014-12-08 | 2016-06-15 | Novartis AG | Cytomegalovirus antigens |
| CA2987155A1 (en) | 2015-06-10 | 2016-12-15 | Hookipa Biotech Ag | Hpv vaccines |
| JP6921833B2 (ja) | 2015-10-22 | 2021-08-18 | モデルナティーエックス， インコーポレイテッド | ヒトサイトメガロウイルスワクチン |
| IL314371A (en) * | 2015-11-04 | 2024-09-01 | Hookipa Biotech Gmbh | Vaccines against hepatitis B virus |
| PT3373959T (pt) | 2015-11-12 | 2022-08-09 | Hookipa Biotech Gmbh | Partículas de arenavírus como vacinas contra o cancro |
| WO2017156146A1 (en) * | 2016-03-08 | 2017-09-14 | University Of Vermont And State Agricultural College | Modified arenavirus |
| KR102574810B1 (ko) | 2016-04-15 | 2023-09-08 | 더 트러스티스 오브 더 유니버시티 오브 펜실베니아 | 습성 연령 관련 황반 변성의 치료를 위한 조성물 |
| AU2017345766A1 (en) * | 2016-10-21 | 2019-05-16 | Modernatx, Inc. | Human cytomegalovirus vaccine |
| JP2019533690A (ja) | 2016-11-04 | 2019-11-21 | ホオキパ バイオテック ジーエムビーエイチ | 癌ワクチンとしての複製欠損性アレナウイルス粒子及び３セグメント型アレナウイルス粒子 |
| UY37679A (es) | 2017-04-14 | 2018-11-30 | Regenxbio Inc | Tratamiento de mucopolisacaridosis ii con iduronato-2-sulfatasa (ids) humana recombinante producida por células neurales o gliales humanas |
| WO2018204080A1 (en) * | 2017-05-02 | 2018-11-08 | The Scripps Research Institute | Compositions and methods related to arenavirus immunogens |
| JP2021535730A (ja) * | 2018-05-11 | 2021-12-23 | シティ・オブ・ホープCity of Hope | 複数の部位メガロウイルス（ｃｍｖ）抗原の発現のためのｍｖａベクター及びその使用 |
| JP7584405B2 (ja) | 2018-10-17 | 2024-11-15 | グラクソスミスクライン バイオロジカルズ ソシエテ アノニム | 改変されたサイトメガロウイルスタンパク質及び安定化された複合体 |
| CN113164585B (zh) * | 2018-12-10 | 2023-08-29 | Km生物医薬股份公司 | 用于预防或治疗巨细胞病毒的先天性感染的疫苗 |
| US20220380805A1 (en) | 2019-11-07 | 2022-12-01 | Universität Basel | Arenaviruses as vectors |
| KR102837045B1 (ko) * | 2020-06-09 | 2025-07-23 | 케이엠 바이올로직스 가부시키가이샤 | 사이토메갈로바이러스의 gB와 펜타머의 융합 단백질 및 당해 융합 단백질을 포함하는 백신 |
| US11406703B2 (en) | 2020-08-25 | 2022-08-09 | Modernatx, Inc. | Human cytomegalovirus vaccine |
| RU2756557C1 (ru) * | 2020-11-02 | 2021-10-01 | Федеральное государственное бюджетное учреждение "Федеральный центр охраны здоровья животных" (ФГБУ "ВНИИЗЖ") | Способ опосредованного определения титра вируса ящура в неинактивированном сырье для вакцины при амплификации вирусной нуклеиновой кислоты и детекции РНК-ампликонов с применением технологии молекулярных биконов |
| US20240117328A1 (en) | 2021-02-10 | 2024-04-11 | Regenxbio Inc. | Treatment of mucopolysaccharidosis ii with recombinant human iduronate-2-sulfatase (ids) |
| US20240229073A1 (en) | 2021-05-13 | 2024-07-11 | Hookipa Biotech Gmbh | Arenaviruses as vectors |
| WO2024163912A2 (en) * | 2023-02-03 | 2024-08-08 | The Children's Medical Center Corporation | Vaccine and therapeutic protein delivery compositions comprising fusion proteins |
| WO2025056782A1 (en) | 2023-09-15 | 2025-03-20 | Hookipa Biotech Gmbh | Arenavirus formulations, methods and uses thereof |
| CN118221773B (zh) * | 2024-02-05 | 2025-09-09 | 首都医科大学附属北京儿童医院保定医院 | 与HLA相关的CMV pp65表位疫苗组合物与应用 |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5057540A (en) | 1987-05-29 | 1991-10-15 | Cambridge Biotech Corporation | Saponin adjuvant |
| DE68929478T2 (de) * | 1988-01-29 | 2004-04-29 | Aventis Pasteur | Rekombinante CMV-Neutralisierungsproteine |
| US4912094B1 (en) | 1988-06-29 | 1994-02-15 | Ribi Immunochem Research Inc. | Modified lipopolysaccharides and process of preparation |
| EP1655305A3 (en) * | 2000-03-21 | 2006-09-13 | Genzyme Corporation | Therapeutic anti-cytomegalovirus compounds |
| DE102004034461B4 (de) * | 2004-07-16 | 2008-02-07 | Chemotherapeutisches Forschungsinstitut Georg-Speyer-Haus | Gentherapie solider Tumore durch retrovirale, mit Arenavirus-Glykoprotein pseudotypisierte Vektoren |
| CA2597921A1 (en) * | 2005-02-15 | 2007-04-26 | University Of North Carolina At Chapel Hill | New live virus vaccines |
| US8173657B2 (en) | 2006-03-23 | 2012-05-08 | Novartis Ag | Imidazoquinoxaline compounds as immunomodulators |
| WO2007109812A2 (en) | 2006-03-23 | 2007-09-27 | Novartis Ag | Immunopotentiating compounds |
| ES2438773T3 (es) * | 2007-12-27 | 2014-01-20 | Universität Zürich | Vectores arenavíricos defectuosos en la replicación |
| US8580276B2 (en) * | 2009-06-05 | 2013-11-12 | City Of Hope | Genetically stable recombinant modified vaccinia ankara (rMVA) vaccines and methods of preparation thereof |
| JP2012530500A (ja) * | 2009-06-26 | 2012-12-06 | ヴェクトライト バイオメディカ インコーポレイテッド | サイトメガロウイルス由来のペプチドを含む免疫原組成物および使用方法 |
| WO2012049317A2 (en) * | 2010-10-15 | 2012-04-19 | Glaxosmithkline Biologicals S.A. | Novel antigen |
| JP2014502848A (ja) | 2011-01-07 | 2014-02-06 | バイオサイエンス・スロバキア | ウイルス診断 |
| WO2012162428A1 (en) | 2011-05-23 | 2012-11-29 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Prime-boost vaccination for viral infection |
| CA2840989A1 (en) * | 2011-07-06 | 2013-01-10 | Novartis Ag | Immunogenic combination compositions and uses thereof |
| US8834307B2 (en) | 2011-10-06 | 2014-09-16 | Kawasaki Jukogyo Kabushiki Kaisha | Belt type continuously variable transmission |
| EP2766385A2 (en) * | 2011-10-12 | 2014-08-20 | Novartis AG | Cmv antigens and uses thereof |
| CN104853771A (zh) * | 2012-07-06 | 2015-08-19 | 诺华股份有限公司 | 巨细胞病毒蛋白的复合物 |
| WO2014140301A1 (en) | 2013-03-15 | 2014-09-18 | Université De Genève | Anti-mycobacterial vaccines |
| PL3077519T3 (pl) | 2013-12-03 | 2021-10-18 | Hookipa Biotech Gmbh | Szczepionki CMV |
| US10722564B2 (en) * | 2014-11-13 | 2020-07-28 | Université de Genéve | Tri-segmented arenaviruses as vaccine vectors |
| CA2987155A1 (en) | 2015-06-10 | 2016-12-15 | Hookipa Biotech Ag | Hpv vaccines |
| IL314371A (en) | 2015-11-04 | 2024-09-01 | Hookipa Biotech Gmbh | Vaccines against hepatitis B virus |
| PT3373959T (pt) | 2015-11-12 | 2022-08-09 | Hookipa Biotech Gmbh | Partículas de arenavírus como vacinas contra o cancro |
| IL314272A (en) | 2016-05-18 | 2024-09-01 | Hookipa Biotech Gmbh | Three-segmented PICHINDE viruses as vaccine vectors |
| JP2019533690A (ja) | 2016-11-04 | 2019-11-21 | ホオキパ バイオテック ジーエムビーエイチ | 癌ワクチンとしての複製欠損性アレナウイルス粒子及び３セグメント型アレナウイルス粒子 |
| AU2018247958A1 (en) | 2017-04-07 | 2019-10-10 | Hookipa Biotech Gmbh | Arenavirus particles to treat solid tumors |
| US20220380805A1 (en) | 2019-11-07 | 2022-12-01 | Universität Basel | Arenaviruses as vectors |
| MX2022014725A (es) | 2020-05-29 | 2023-02-09 | Hookipa Biotech Gmbh | Estrategias de tratamiento del cáncer mediante el uso de vectores de arenavirus. |
-
2014
- 2014-12-03 PL PL14820762T patent/PL3077519T3/pl unknown
- 2014-12-03 EP EP14820762.4A patent/EP3077519B1/en active Active
- 2014-12-03 ES ES14820762T patent/ES2868427T3/es active Active
- 2014-12-03 PT PT148207624T patent/PT3077519T/pt unknown
- 2014-12-03 JP JP2016536893A patent/JP6818551B2/ja active Active
- 2014-12-03 HU HUE14820762A patent/HUE054579T2/hu unknown
- 2014-12-03 EP EP21165671.5A patent/EP3904522A1/en not_active Withdrawn
- 2014-12-03 US US15/101,363 patent/US10111945B2/en active Active
- 2014-12-03 DK DK14820762.4T patent/DK3077519T3/da active
- 2014-12-03 CA CA2932318A patent/CA2932318C/en active Active
- 2014-12-03 HR HRP20211015TT patent/HRP20211015T1/hr unknown
- 2014-12-03 WO PCT/EP2014/076466 patent/WO2015082570A1/en not_active Ceased
- 2014-12-03 LT LTEP14820762.4T patent/LT3077519T/lt unknown
- 2014-12-03 RS RS20210759A patent/RS61993B1/sr unknown
- 2014-12-03 SI SI201431830T patent/SI3077519T1/sl unknown
- 2014-12-03 CN CN202210602284.6A patent/CN115058452A/zh active Pending
- 2014-12-03 CN CN201480074709.4A patent/CN105980570B/zh active Active
- 2014-12-03 AU AU2014359276A patent/AU2014359276B2/en active Active
-
2018
- 2018-09-20 US US16/137,323 patent/US11554169B2/en active Active
-
2020
- 2020-12-28 JP JP2020218641A patent/JP7001807B2/ja active Active
-
2021
- 2021-04-26 AU AU2021202541A patent/AU2021202541A1/en not_active Abandoned
- 2021-06-29 CY CY20211100578T patent/CY1124288T1/el unknown
-
2022
- 2022-11-22 US US18/058,116 patent/US20230181725A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| WO2015082570A8 (en) | 2015-11-26 |
| PT3077519T (pt) | 2021-05-13 |
| US20160296619A1 (en) | 2016-10-13 |
| HK1226440A1 (zh) | 2017-09-29 |
| CN115058452A (zh) | 2022-09-16 |
| JP2017503482A (ja) | 2017-02-02 |
| CY1124288T1 (el) | 2022-07-22 |
| EP3077519A1 (en) | 2016-10-12 |
| EP3077519B1 (en) | 2021-03-31 |
| EP3904522A1 (en) | 2021-11-03 |
| US20230181725A1 (en) | 2023-06-15 |
| PL3077519T3 (pl) | 2021-10-18 |
| CA2932318C (en) | 2023-10-10 |
| US20190247493A1 (en) | 2019-08-15 |
| DK3077519T3 (en) | 2021-06-14 |
| CN105980570B (zh) | 2022-06-07 |
| CN105980570A (zh) | 2016-09-28 |
| AU2014359276B2 (en) | 2021-01-28 |
| HRP20211015T1 (hr) | 2021-10-01 |
| AU2014359276A1 (en) | 2016-06-16 |
| JP2021061848A (ja) | 2021-04-22 |
| SI3077519T1 (sl) | 2021-07-30 |
| US11554169B2 (en) | 2023-01-17 |
| WO2015082570A1 (en) | 2015-06-11 |
| CA2932318A1 (en) | 2015-06-11 |
| HUE054579T2 (hu) | 2021-09-28 |
| AU2021202541A1 (en) | 2021-05-27 |
| ES2868427T3 (es) | 2021-10-21 |
| JP7001807B2 (ja) | 2022-02-04 |
| LT3077519T (lt) | 2021-04-26 |
| RS61993B1 (sr) | 2021-07-30 |
| US10111945B2 (en) | 2018-10-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7001807B2 (ja) | Ｃｍｖワクチン | |
| JP6914950B2 (ja) | Ｂ型肝炎ウイルスに対するワクチン | |
| Paillot et al. | Equine herpes virus-1: virus, immunity and vaccines | |
| CN107921117B (zh) | Hpv疫苗 | |
| CN114096675A (zh) | 冠状病毒免疫原性组合物和其用途 | |
| CN109843323B (zh) | 用于黄病毒疫苗接种的组合物和方法 | |
| JP2003180385A (ja) | コロナウイルスに対するワクチン接種用組成物および方法 | |
| Kohlmann et al. | Protective efficacy and immunogenicity of an adenoviral vector vaccine encoding the codon-optimized F protein of respiratory syncytial virus | |
| US20220016234A1 (en) | Anti covid-19 therapies using nucleocapsid and spike proteins | |
| US11975063B2 (en) | Recombinant chimeric bovine/human parainfluenza virus 3 expressing rsv g and its use | |
| JP2018517722A (ja) | 多価エンテロウイルス（Ｅｎｔｅｒｏｖｉｒｕｓ）ワクチン組成物およびそれに関連する使用 | |
| JP7642608B2 (ja) | ハンタウイルス抗原性組成物 | |
| JP2024502837A (ja) | 高病原性コロナウイルスに対する細胞傷害性ｔ細胞免疫療法 | |
| HK40063367A (en) | Cmv vaccines | |
| Sahin et al. | Assessment of the immunogenicity and protective aspects of a DNA vaccine targeting Crimean Congo hemorrhagic fever virus glycoprotein Gc | |
| HK1226440B (en) | Cmv vaccines | |
| CN120442567A (zh) | 狂犬病毒糖蛋白嵌合重组水泡性口炎病毒及其应用 | |
| TW201026324A (en) | HLA-A2-restricted T-cell epitopes of the respiratory syncytial virus fusion protein as peptide-based vaccines | |
| AUPERIN | Construction and Evaluation of Recombinant Virus |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20160826 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20171201 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20171201 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20181015 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20181023 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20190118 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20190423 |
|
| A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A712 Effective date: 20190508 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20190423 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20190508 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20200115 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20200212 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20200507 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20200812 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20200813 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20201201 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20201228 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 6818551 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |